PetMed Express (NASDAQ:PETS) Posts Earnings Results, Misses Expectations By $0.01 EPS

PetMed Express (NASDAQ:PETS) issued its quarterly earnings data on Tuesday. The company reported ($0.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by ($0.01), FiscalAI reports. PetMed Express had a negative return on equity of 70.81% and a negative net margin of 35.51%.The business had revenue of $42.82 million for the quarter, compared to analyst estimates of $52.00 million. During the same quarter in the prior year, the firm posted ($0.56) earnings per share.

Here are the key takeaways from PetMed Express’ conference call:

• PetMed Express said fiscal 2026 was a “pivotal year” focused on stabilizing the business, improving internal controls, and restoring regulatory compliance, including filing delayed reports and remediating three previously disclosed material weaknesses.
• Revenue declines slowed in the second half, and Q4 net sales rose sequentially versus Q3 for the first time in a fourth quarter since fiscal 2024, with management citing early traction in prescription meds, food sales, and autoship signups.
• Full-year sales fell 21.1% to $179 million, while Q4 revenue declined 15.6% year over year, showing the company is still dealing with substantial top-line pressure.
• Management highlighted meaningful cost actions, including exiting underperforming vendor relationships that should generate about $6.1 million in annualized savings, along with lower G&A from broader optimization efforts.
• The company ended the year with $21.4 million in cash and no debt, but full-year adjusted EBITDA was negative $15.4 million and net loss widened significantly due to goodwill impairment, inventory write-downs, and legal/severance costs.

PetMed Express Price Performance

NASDAQ PETS opened at $2.13 on Wednesday. PetMed Express has a 12 month low of $1.57 and a 12 month high of $4.32. The firm has a market capitalization of $45.58 million, a PE ratio of -0.68 and a beta of 0.77. The company’s 50 day simple moving average is $2.27 and its 200 day simple moving average is $2.61.

Wall Street Analyst Weigh In

Several analysts have weighed in on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of PetMed Express in a research note on Tuesday, May 12th. Zacks Research raised PetMed Express to a “hold” rating in a research note on Thursday, April 30th. One equities research analyst has rated the stock with a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, PetMed Express presently has an average rating of “Reduce”.

Hedge Funds Weigh In On PetMed Express

A number of institutional investors and hedge funds have recently added to or reduced their stakes in PETS. Empowered Funds LLC increased its position in shares of PetMed Express by 14.2% during the 4th quarter. Empowered Funds LLC now owns 68,651 shares of the company’s stock valued at $220,000 after purchasing an additional 8,535 shares during the period. Man Group plc lifted its holdings in shares of PetMed Express by 10.7% in the fourth quarter. Man Group plc now owns 167,152 shares of the company’s stock valued at $535,000 after buying an additional 16,113 shares during the period. Bridgeway Capital Management LLC lifted its holdings in shares of PetMed Express by 17.2% in the fourth quarter. Bridgeway Capital Management LLC now owns 126,351 shares of the company’s stock valued at $404,000 after buying an additional 18,535 shares during the period. Jain Global LLC bought a new position in PetMed Express during the fourth quarter valued at about $78,000. Finally, Steel Partners Holdings L.P. bought a new position in PetMed Express during the fourth quarter valued at about $620,000. 73.33% of the stock is owned by institutional investors.

About PetMed Express

PetMed Express, Inc operates as an online and catalog-based pet pharmacy and retail supplier under the 1-800-PetMeds brand name. The company distributes prescription and non?prescription medications, nutritional supplements, flea and tick control products, and a range of pet health supplies directly to consumers. Through its licensed veterinary pharmacy in Delray Beach, Florida, PetMed Express fills orders for dogs, cats and other companion animals, offering both branded and generic products alongside its own private?label formulations.

Founded in 1996 by Marc Puleo, PetMed Express built its business on the premise of convenience and cost savings for pet owners seeking reliable access to veterinary medications.